The finding that certain neoplasms have a requirement for L-asparagine, an amino acid commonly regarded as nutritionally nonessential, provides the basis of a unique form of cancer therapy.
In 1953, Kidd (1, 2) observed that certain transplanted murine leukemias were suppressed by treatment with guinea pig serum, The work of Broome (3) (4) (5) established that the active factor in guinea pig serum is L-asparaginase. x His main evidence was as follows: First, the chemical properties of the leukemia-inhibitory factor did not differ from those of L-asparaginase of guinea pig serum, and in various fractionation procedures the leukemia-inhibitory activity was always associated with T-asparaginase activity. Secondly, 6C3HED, the leukemia used in his studies, was found to require Lasparagine for optimal growth in culture, and cells cultured continuously in the presence of I.-asparagine retained their sensitivity to suppression by guinea pig sera in vivo; on the other hand, sublines of 6C3HED that hadlost their requirement for l.-asparagine as a result of culture in vitro in media lacking l.-asparagine were no longer suppressed by guinea pig serum in vivo. Finally, sublines of 6C3HED that had been made resistant to guinea pig serum by exposure to subeffectlve doses in vivo did not require L-asparagine for immediate growth in culture.
Later studies provide further evidence that the leukemia-inhibitory factor in guinea pig serum is l.-asparaginase. First, the sera of animals closely related to the guinea pig (three genera of the same supeffAmily, Ca~oidea) have both L-asparaginase and leukemia-inhibitory activities (6, 7) ; in contrast, no serum lacking L-asparaginase is effective against leukemias (1, (5) (6) (7) (8) . Secondly, l.-asparaginase prepared from a bacterial source, F.scherich~ coU~ suppresses 6C3HED and the DBA/2 leukemia P1534 This communication is concerned with a comparison between L-asparaginase from guinea pig serum and L-asparaginase from E. coli in the treatment of the transplanted radiation-induced leukemia EARAD1. In addition, we have extended our previous survey of murine leukemias (11) to a total of 109 leukemias that have now been tested for susceptibility to guinea pig serum.
Materials and Methods
Leukemias.--AU the leukemias used in this study were induced, or arose spontaneously, in mice of our colonies. Methods of induction by X-radiation, chemical carcinogens, and leukemia viruses (Gross, Friend, Moloney, Ranscher) are described in previous publications from this laboratory (see reference 14) . The leukemia used in most of the studies reported here, EARAD1, was induced by X-radiation in a (C57BL/6 X A)FI hybrid female of our colony in 1961 and has been maintained exclusively by passage in isogenic (C57BL/6 X A)F, 9 mice. At the time of these experiments, it was in its 27th-148th transplant generations.
Guinea Pig Serum (GPS).--Hartley gtfinca pigs weighing more than 350 g were bled from the heart under ether anesthesia, the sera were pooled after separation and centrifugation, and the pools were stored at -70°C. The L-asparaginase activity of these pooh ranged from 115-140 units/ml. Table HI leukemias were tested for sensitivity to GPS by inoculating a counted number of viable cells (usually 1 X 109 subcutaneously into 10 isogenic mice, five of which received I mi of GPS intravenously and 1 ml intraperitoneally within an hour of the inoculation of the leukemia cells, the other five serving as controls. Sensitivity to GPS was indicated by either complete protection or marked prolongation of survival time.
Tests of Leukemias of Various Types for their Sensitivity to GPS.--Ym the survey summarized in
Enzyme Assays.--The L-asparaginase assays were carried out as described elsewhere (10) . One unit of activity is that quantity of enzyme which releases 1 zmole of ammoni~ from Lasparagine per hour at the maximum rate. The clearance of GPS and E. coli (EC-1 and EC-2) L-asparaginases was determined by injecting the stated amount of GPS or enzyme preparation intravenously or intraperitoneally as indicated in Fig. 5 . Blood was obtained by cardiac puncture from two mice for each time interval, and the pooled serum was stored frozen until assayed for x-asparaginase.
Preparation of the L-asparaginases EC-1 and EC-g from E. coli B ¢dls.--The preparation of EC-1 and EC-2 is described fully in a separate report dealing with the chemistry of the two enzymes (10) . In summary, a ceU-frec extract of E. coli B cells is treated with M-.nCh to precipitate nucleic acids and the two enzymes are partially separated by fractional precipitation with ammonium sulphate; further separation of EC-1 and EC-2 is effected by chromatography on hydroxylapatite and DEAE-ceUulose columns. With the exception of the EC-1 preparation used in studying clearance rates (Fig. 5) , all the experiments reported here were performed with the leukemia-inhibitory r:-asparaginase EC-2. Table I shows the effect of GPS administered in various doses and by various routes on the outgrowth of 1 X 10 6 cells of the GPS-sensitive leukemia EARAD1 inoculated subcutaneously approximately 1 hr before the administration of GPS. The subcutaneous route (distant from the site of leukemia inoculation), the intraperitoneal route, and the intravenous route of injection were almost equally effective. This pool of GPS produced complete suppression of EARAD1 at a dose of 0.5 ml; a dose of 0.1 ml caused slight prolongation of survival but no absolute protection. Table II indicates that the effectiveness of GPS is related to the number of leukemia cells inoculated. With 1 ml GPS injected intravenously at the time of inoculation of leukemia cells there was complete protection of all mice inoculated with 1 X 10 e EARAD1 cells and of some mice inoculated with 3 X 106 cells. There were no survivors in groups receiving 9 X l0 s or more cells. Increased survival time was observed in all mice given GPS, regardless of the number of cells in the inoculum.
RESULTS

Sensitivity of Leukemia EARAD1 to GPS.--
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Survey of a Series of Murine Leukemias for their Sensitivity to GPS.--Table
III is a summary of our experience up to the present time regarding the incidence of sensitivity to GPS among leukemias of several types. The 109 leukemias listed in Table III were for the most part in very early transplant generations and include the 18 leukemias reported previously (11) . Sensitivity is evidently a common characteristic of certain classes of leukemia; in particular, of leukemias induced by X-radiation (21/48) and of leukemias arising spontaneously in strains that have a low incidence of leukemia, 5/14 in the C57BL/ 6, A, BALB/c, I and DBA/2 strains. Of leukemias arising spontaneously or induced in strains that have a high incidence of leukemia, sensitivity to GPS is uncommon, 1/12 in the AKR and C58 strains. No instance of sensitivity was 
Effectiveness of GPS in Comparison with a Number of Commonly Used
Chemotherapeutic Agents.--Three leukemia.s, two of them GPS-sensitive, and one GPS-resistant, were selected for the experiments shown in Table IV . With the exception of their response to GPS all three leukemias showed approximately similar sensitivities to each particular chemotherapeutic agent. In other words, the two GPS-sensitive leukemias did not differ from the GPS-resistant leukemia in their responses to this range of cytotoxic drugs. A striking feature of such comparative studies, in addition to the remarkable effectiveness of GPS in affording absolute protection, is that GPS-treated mice show no weight loss or signs of toxicity. (Survival times of mice with EARAD1 were not affected by the administration of 2.5 g/kg D-asparagine or L-asparagine daily for 10 days.) 
Comparative Effectiveness of E. coll z-asparaginase and GPS, under Various Conditions of Testing, in the Treatment of Leukemia EARADI.--
* With the exception of GPS, cytoxan, and prednisone, all compounds were administered in 10 daily doses, starting 4 hr after subcutaneous inoculation of 10 e leukemia cells. Predaisone was injected for 10 days twice daily subcutaneously, except for day 0 when the total daily dose was given in one intraperitoneal injection. Cytoxan was given on day 0 only. With the exceptions noted, all injections were intraperitoneal.
~; Origins of these leukemias of the A strain are given in reference 15. § Based on survival times of 20 control mice treated with the diluent (saline or earboxymethylceUulose), or not injected.
]] NSC 50339 ffi 2-chloro-4~,4n-bis(2-imidazolin-2-yl)terephtha~anilide. . In contrast to the failure of EC-2 to protect when administered at the time of inoculation of EARAD1, EC-2 was highly effective in the treatment of these established 7-day transplants. Guinea pig serum, on the contrary, is relatively less effective when administered after the leukemia is established. Suppression by EC-2 was most marked at 2000 units, with one permanent cure in the group of four mice (Table V) . ,ii __..Leuk°m'cm'ce'rea' w'th""ne Treatment of nonleukemic animals with EC-2 preparations of the type used in these tests does not cause loss of weight or obvious toxicity, although leukemic animals lose weight which they recover after treatment (Fig. 4) .
Permanent Cure of Mice with Established Leukemic Transplants by Treatment ~ith EC-2 Beginning on the 7tk Day after Inoculation of Leukemia Cells.--A
high proportion of mice with 7-day transplants of EARAD 1 can be permanently Sacrificed with recurrence on day 3~ (C57BL/6 X A)F1 ~ leukemia EARAD1 inoculated s.c. on day 0 into (C57BL/6 X A)FI mice (average weight, 20 g). Treatment started on day 7, at which time the subcutaneous mass measured 10 X 10 mm (average). 10 injections (two per day) on days 7-11. In all treated animals the s.c. mass was no longer visible or palpable on day 9. * Specific activity: 315 uuits/mg protein.
Transplanted and identified as resistant variant by failure to respond to GPS.
cured by treatment with 2000 or more units of EC-2. All survivors from the experiment shown in Table VI were observed for at least 6 months after treatment. As these 6-month survivors were fully susceptible to rechaUenge with minimal numbers of EARAD1 cells (Table VI) it is clear that cure must be
SUPPRESSION OF I~[URINE LEUKEMIAS BY L-ASPARAGINASE
ascribed solely to the action of x-asparaginase and not to any immune reaction accompanying therapy with L-asparaginase. Blood Clearance of GPS z,-asparaginase and E. coli z-asparaginase.--Two z-asparaginases, EC-1 and EC-2, have been isolated from E. coli (10) . They can be partially separated by (NH4)2SO4-fractionation and they differ in chromatographic properties and in enzymatic activity in relation to pH. Only EC-2 has leukemia-inhibitory activity. contrast, EC-2 is cleared rapidly, the rates for intraperitoneal and intravenous injection being similar except for the period of equilibration (half-life approximately 150 rain). No rate of clearance from the blood can be estimated for enzyme EC-1 because apparently very little of the enzyme left the peritoneal cavity, or alternatively the half-life of the enzyme in vivo is very short (Fig. 5 ).
DISCUSSION
As a preliminary to discussion of the findings reported here we may consider the accumulated evidence that the inhibitory factor in GPS is L-asparaginase and that the inhibition of GPS-sensitive neoplastic cells is a consequence of a specific nutritional requirement for L-asparagine.
I. Fractlonation of GPS (3, 4, (16) (17) (18) (19) (20) shows that fractions with inhibitory activity against GPS-sensitive leukemias invariably contain L-asparaginase.
2. Sera that contain L-asparaginase will suppress GPS-sensitive leukemias; sera that do not contain L-asparaginase do not suppress these leukemias (1, 6-8) .
3. Four murine leukemias and one tumor of the rat that have been found to require I,-asparagine for their growth in vitro, (6C3HED (3, 5) , EARAD1 (17), L5178Y (reference 21 and unpublished observations), P1798 (unpublished observations), and Walker carcinosarcoma 256 (22)), are sensitive to suppression by GPS in vivo. Two other cell lines are known to require L-asparagine in vitro, (Jensen rat sarcoma (23) and a hepatoma of the rat (24)), but these have not been tested for sensitivity to GPS in vivo. Conversely, many routine cell lines are known to have no requirement for L-asparagine in vitro and are not sensitive t6 GPS in vivo. During a recent study in this laboratory 12 transplanted routine leukemias that were known to be insensitive to GPS in vivo were successfully grown in culture and none of these exhibited a requirement for I~asparagine (B. Stambuck, B. Williamson, E. A. Boyse, and L. J. Old, in preparation).
4. Cells that lose their requirement for L-asparagine in vitro are no longer suppressed by GPS in vivo and leukemia cells that have been rendered insensitive to GPS by suboptimal treatment in vivo no longer require L-asparagine for growth in vitro; this has been shown for 6C3HED (3, 5) , and for EARAD1 and P1798 (unpublished observations).
5. As reported here and previously (9) L-asparaginase from E. coli is as active as GPS against GPS-sensitive leukemias. The great phylogenetic disparity between these two sources makes it virtually certain that the inhibitory factor in GPS is I.asparaginase and not a protein with properties dosely related to ~-asparaginase; it suggests furthermore that the inhibitory action derives from its deamidating activity and not from other regions of the L-asparaginase molecule.
The finding that certain leukemias and other tumors have a specific nutritional requirement for L-asparagine constitutes the only established instance of a defined biochemical difference between neoplastic cells and their normal precursors. The suppression of such leukemias by L-asparaginase thus constitutes the only specific therapy known at the present time for any form of cancer. The extraordinary effectiveness of L-asparaginase is particularly well illustrated when seen in comparison with various standard chemotherapeutic agents (Table IV) . The virtually all-or-none response to L-asparaginase (depending upon the susceptibility or resistance of particular leukemias) contrasts with the less discriminating and less effective responses to treatment by cytotoxic drugs and hormones, which are exerting differential effects upon neoplastic and normal tissues. Clearly, the absence of toxicity of L-asparaginase, which makes it possible to treat with very high doses, derives from its specificity of action.
The detection of leukemia-inhibitory activity of L-asparaginases from different sources is dependent upon the circumstances under which the enzymes are assayed. GPS L-asparaginase is most effective when administered at the same time as the leukemia cells, under which condition E. coli L-asparaginase confers no protection. In the treatment of established tumors that have already grown to a considerable size, however, EC-2 is considerably more effective than 28 SUPPP~SSION OF MURINE LEUKEMIAS BY L-ASPA-RAGINASE GPS (on the basis of equivalent numbers of units administered). A striking difference between the GPS and E. coli enzymes is the more rapid clearance of the latter (Fig. 5) . The failure of EC-2 in the concurrent treatment of inoculated leukemia may be partly attributable to its rapid clearance, but this cannot be the only factor as it is effective in the treatment of established transplants. It is necessary to postulate that the requirement for L-asparagine is related to phases of the growth cycle of asparagine-dependent cells. Shortly after transplantation the cells may be metabolically inactive and the demand for asparagine correspondingly reduced. Later, when the cells enter a phase of growth their requirement for asparagine is presumably increased and at this time they may become susceptible to asparagine-deprivation once more. This would account for the effectiveness of GPS in the treatment of newly inoculated leukemia cells because asparagine-deprivation in this case would persist beyond the lag-phase of the inoculated cells, whereas in the case of the rapidly cleared EC-2, serum and tissue asparagine may already have returned to levels adequate for growth of the leukemia cells.
The inactivity of other L-asparaginases such as E. coli EC-1 (10) and yeast L-asparaginase (25) can be explained on the basis of exceedingly rapid clearance or inactivation. Other contributory factors may include low activity at physiological pH values; e.g., EC-2 has maximal activity in vitro at pH 7.4 whereas EC-1 has no more than 77% of its optimal activity at this pH (10) .
The permanent cure of mice with disseminated leukemia by treatment initiated 7 days after inoculation is unique, as it is the only instance of its kind in a fully histocompatible system. The conclusion that immunological responses play no part in the recovery of these mice is emphasized by the finding that they are fully susceptible to rechallenge with minimal inocula of the same leukemia. The occurrence in EARAD1 of variants that do not require asparagine appears to be rare, or cures would not be possible. At somewhat lower levels of treatment, recurrence is the rule, but the recurrent leukemia is susceptible to retreatment, indicating regrowth of the sensitive line. As x-asparaginase is effective in retreatment of mice with recurrent leukemia or cured mice receiving a second transplant it is clear that sensitization to L-asparaginase does not occur under these conditions, or that any antibodies which may have been formed do not interfere with enzyme activity.
Of the many important questions raised by the work on L-asparaginase perhaps the most pressing is whether human tumors may be susceptible to this form of therapy. The occurrence of susceptible leukemias in mice, and of susceptible tumors of other kinds in the rat, makes it impossible to form an opinion as to which class of human tumor might respond. However, the availability of an effective enzyme from bacterial sources will make it possible to carry out adequate trials with a wide variety of tumors and leukemias in species other than small rodents. The development of a test capable of revealing asparagine-dependence of primary tumors obviously would be of great value, but regardless of such tests final evaluation is bound to depend upon tests in vivo.
SUMMARY
A survey of 109 recently derived leukemias of the mouse revealed that sensitivity to suppression by guinea pig serum is a common property of transplanted leukemias of certain classes. The sensitive leukemias included five that arose spontaneously in mice of strains with a low incidence of leukemia and 21 that were induced by X-radiation.
Two GPS-sensitive leukemias were not more sensitive than a GPS-resistant leukemia to a range of standard chemotherapeutic agents.
The effectiveness of L-asparaginase EC-2 from Escherich~ coli in suppression of the GPS-sensitive leukemia EARAD1 depends upon the conditions of assay. Whereas it is not inhibitory when administered as a single dose at the time of inoculation of the leukemia it is considerably more effective than GPS when used in the treatment of established leukemia.
Permanent cures of 7-day generalized transplants of EARAD1 can be effected by the administration of 2000 or more units of EC-2. Immunological factors apparently do not contribute to cure as treated survivors are fully susceptible to rechallenge with minimal numbers of cells from the same leukemia. Reinoculated survivors with progressively growing transplants have been successfully retreated with EC-2.
The blood clearance of EC-2 L-asparaginase injected into mice is much more rapid than that of GPS L-asparaginase. After intraperitoneal inoculation of the EC-1 L-asparaginase, which does not have leukemia-inhibitory activity, only very low levels of enzyme activity could be detected in the serum.
The effectiveness of EC-2 from E. coli and its availability from a virtually limitless source wilt make it possible to extend the study of inhibition of leukemias and other tumors by L-asparaginase to species other than small rodents.
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